Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Reviva Pharmaceuticals Holdings Inc. (RVPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: RVPH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9.43
1 Year Target Price $9.43
| 3 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -55.57% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 24.95M USD | Price to earnings Ratio - | 1Y Target Price 9.43 |
Price to earnings Ratio - | 1Y Target Price 9.43 | ||
Volume (30-day avg) 6 | Beta 0.11 | 52 Weeks Range 0.30 - 2.99 | Updated Date 07/8/2025 |
52 Weeks Range 0.30 - 2.99 | Updated Date 07/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.78 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -178.72% | Return on Equity (TTM) -916.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 19885421 | Price to Sales(TTM) - |
Enterprise Value 19885421 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6 | Shares Outstanding 68003600 | Shares Floating 40777801 |
Shares Outstanding 68003600 | Shares Floating 40777801 | ||
Percent Insiders 10.3 | Percent Institutions 20.35 |
Upturn AI SWOT
Reviva Pharmaceuticals Holdings Inc.
Company Overview
History and Background
Reviva Pharmaceuticals Holdings, Inc. is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutics for unmet medical needs in the central nervous system, respiratory, and inflammatory diseases. Founded with the goal to address mental health disorders. They merged with a special purpose acquisition company (SPAC) to become publicly traded.
Core Business Areas
- Central Nervous System (CNS): Focuses on developing therapies for schizophrenia, depression, and other CNS disorders. The lead compound is Bucindolol, targeting schizophrenia and potentially other psychiatric conditions.
Leadership and Structure
Reviva Pharmaceuticals' leadership includes experienced executives and scientists with expertise in drug development. The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- Bucindolol: Bucindolol is Reviva's lead product candidate, a dopamine D2/serotonin 5-HT2A receptor modulator being developed for the treatment of schizophrenia and potentially other psychiatric disorders. Bucindolol does not have direct market share as it is under clinical development. The schizophrenia market is highly competitive with established players like Janssen (INVEGA), Otsuka (ABILIFY), and Alkermes (ARISTADA). Revenue associated with this product is contingent on FDA approval and subsequent sales.
Market Dynamics
Industry Overview
The biopharmaceutical industry for CNS disorders is characterized by high unmet needs, significant research and development investments, and stringent regulatory requirements. Increasing prevalence of mental health disorders drives demand for innovative therapies.
Positioning
Reviva is positioned as a company focusing on novel mechanisms of action in CNS disorders. Their competitive advantage lies in the potential for Bucindolol to offer improved efficacy and safety profiles compared to existing treatments.
Total Addressable Market (TAM)
The schizophrenia market is estimated to be worth billions of dollars annually. Reviva is positioning Bucindolol to capture a portion of this large market if approved, focusing on patients who may not respond adequately to current treatments. Global Schizophrenia Drugs Market Size Expected to Reach USD 9.54 Billion in 2032, According to Emergen Research.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action for Bucindolol
- Focus on unmet medical needs
- Experienced leadership team
- Potentially improved safety profile compared to existing antipsychotics.
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- Lack of established commercial infrastructure
- High risk associated with drug development
Opportunities
- Potential for FDA approval of Bucindolol
- Partnerships with larger pharmaceutical companies
- Expansion into other CNS indications
- Government funding for mental health research
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- JNJ
- LLY
- ABBV
Competitive Landscape
Reviva is a smaller player compared to established pharmaceutical companies. Its success depends on demonstrating superior efficacy and safety with Bucindolol.
Growth Trajectory and Initiatives
Historical Growth: Growth is tied to the advancement of Bucindolol through clinical development stages.
Future Projections: Future growth is contingent on successful clinical trials, regulatory approval, and commercialization of Bucindolol. Analyst estimates vary widely depending on clinical trial outcomes.
Recent Initiatives: Reviva has focused on advancing Bucindolol through Phase 3 clinical trials and seeking strategic partnerships.
Summary
Reviva Pharmaceuticals is a high-risk, high-reward biopharmaceutical company focused on CNS disorders. The company's future hinges on the successful development and commercialization of Bucindolol. While the potential market is substantial, Reviva faces significant challenges including clinical trial risks, regulatory hurdles, and competition from established players. Securing partnerships and funding are critical for the company's long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, industry reports, financial news sources.
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Reviva Pharmaceuticals Holdings Inc.
Exchange NASDAQ | Headquaters Cupertino, CA, United States | ||
IPO Launch date 2018-10-18 | Founder, CEO, President & Director Dr. Laxminarayan Bhat Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.revivapharma.com |
Full time employees 14 | Website https://www.revivapharma.com | ||
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.